Navigation Links
ADVENTRX Announces 9-Month Stability Data Results for ANX-530
Date:6/30/2010

SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced the results of stability tests performed on samples of ANX-530 (vinorelbine injectable emulsion), or Exelbine™, manufactured at the Company's intended commercial manufacturing site.  The 9-month stability data are on track to support the submission of a New Drug Application (NDA) for Exelbine.  

"These results are consistent with our expectations and what we anticipate from the 12-month data," said Brian M. Culley, Chief Executive Officer of ADVENTRX. "Once the 12-month data is analyzed, we will prepare and submit the Exelbine NDA, which we expect will take place in the fourth quarter of this year."

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use.  More information can be found on the Company's web site at www.adventrx.com.  

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements.  These risks and uncertainties include, but are not limited to: the risk that future stability testing results are not consistent with prior results or are out-of-specification or otherwise do not support comparability between ADVENTRX's prior and intended commercial manufacturing sites or a commercially-viable expiration dating period; the risk that the FDA does not accept a submitted Exelbine NDA for review, including as a result of identifying clinical or nonclinical reasons for a refusal-to-file or identifying CMC reasons that were not identified in the refusal-to-file of the previously submitted Exelbine NDA; ADVENTRX's dependence on the success of Exelbine, and uncertainty as to whether Exelbine will receive regulatory approval or be commercialized successfully; the risk that the bioequivalence data and other information included in the Exelbine NDA may not adequately support bioequivalence with Navelbine®; the potential that changes made in transferring the manufacturing process for Exelbine may result in a lack of comparability between the commercial product and the material used in the bioequivalence trial, and that the FDA may require ADVENTRX to perform additional nonclinical, bioequivalence or clinical studies; the potential for the FDA to impose other requirements to be completed before or after approval of the Exelbine NDA; the risk that ADVENTRX will pursue development activities at levels or on timelines, or will incur unexpected expenses, that shortens the period through which its operating funds will sustain it; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.  

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made.  ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ADVENTRX Added to Russell Microcap Index
2. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on May 17
3. ADVENTRX Pharmaceuticals Announces Closing of Financing
4. ADVENTRX Reverse Split Effective; Trading on Adjusted Basis Begins Today
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
6. ADVENTRX Receives Brand Name Acceptance for ANX-530
7. ADVENTRX Receives Refuse to File Letter from FDA on ANX-530 New Drug Application
8. ADVENTRX Announces Management Promotions
9. ADVENTRX Appoints Icahn Representative to Board of Directors
10. ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9
11. ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences Virtual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Following receiving ... Israel , s AMAR is a major milestone ... M w ound care market in ... BST for inclusion in the National Health Basket ...   E-QURE Corp. (OTCQB: EQUR), a leader in ...
(Date:2/24/2017)... 24, 2017 Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... The Global Empty Capsules Market is poised ... to reach approximately $2.9 billion by 2025. This industry ... on global as well as regional levels presented in the research scope. ...
(Date:2/24/2017)... Pa. , Feb. 24, 2017 Physician ... of Drug and Alcohol Programs Jennifer Smith ... in providing training for and using naloxone, a life-saving ... Mark McCullough , a recovery specialist and overdose survivor ... by EMS providers. "A significant part of ...
Breaking Medicine Technology:
(Date:2/27/2017)... Arizona (PRWEB) , ... February 27, 2017 , ... ... Center for Shamanic Healing and Spiritual Awakening, is happy to announce her ... for mind and body, these individual customized retreats offer the winter-weary soul an ...
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... Periodontitis is a chronic inflammatory gum condition that occurs when the bacteria in plaque ... cleaning, also referred to as a scaling and root planing or SRP, and can ...
(Date:2/27/2017)... ... 27, 2017 , ... Texas based retail electric company Discount ... RCE (Residential Customer Equivalent) count exceeds 150,000. , Discount Power was ... and 2,250 RCEs at the time of acquisition. In the three years since ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... New Jersey ... rates, among all types and genders. And the need for advanced services is growing. ... and its top-rated cancer care program, in collaboration with their non-profit partners in their ...
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care agency based in ... Palo Alto, is proud to announce an important upgrade to its geographic information pages, ... care close to home, and by having city-specific pages, NuevaCare is answering that information ...
Breaking Medicine News(10 mins):